High-risk symptoms and quantitative faecal immunochemical test accuracy: Systematic review and meta-analysis

Table 5 OC-Sensor^® diagnostic accuracy parameters for colorectal cancer detection (Threshold 10 µg Hb/g faeces) estimated with DerSimonian vs Bivariate methods

Variable	Studies (n)	Sensitivity1	Specificity1	Positive LR2	Negative LR2	Diagnostic OR2
All studies (DS)	8	90.8 (87.9-93.2)	79.9 (79.1-80.7)	4.79 (2.96-7.76)	0.15 (0.09-0.23)	31.44 (19.50-50.68)
All studies (Bv)	8	89.6 (82.7-94.0)	80.2 (67.2-88.9)	4.52 (2.73-7.50)	0.13 (0.08-0.20)	34.85 (20.74-58.57)
100% Symptomatic (DS)	4	94.4 (91.4-96.6)	65.9 (64.4-67.4)	2.97 (1.78-4.95)	0.10 (0.06-0.15)	28.49 (17.77-45.67)
100% Symptomatic (Bv)	4	94.1 (90.0-96.6)	66.0 (47.1-80.9)	2.77 (1.69-4.55)	0.09 (0.06-0.14)	30.93 (16.09-59.45)
Mixed patients (DS)	4	83.2 (76.5-88.6)	88.2 (87.4-89.0)	7.78 (4.72-12.82)	0.21 (0.13-0.33)	35.36 (14.19-88.10)
Mixed patients (Bv)	4	85.5 (76.5-91.4)	89.3 (84.1-93.0)	8.01 (5.07-12.65)	0.16 (0.10-0.28)	49.35 (19.88-122.5)
CRC prevalence ≥ 2.5% (DS)	5	91.9 (88.7-94.3)	69.7 (68.5-71.0)	3.16 (1.99-5.0 )	0.13 (0.07-0.25)	23.20 (14.76-36.47)
CRC prevalence ≥ 2.5% (Bv)	5	91.7 (83.3-96.1)	69.3 (53.5-81.6)	2.99 (1.97-4.53)	0.12 (0.07-0.21)	24.95 (16.02-38.86)
CRC prevalence < 2.5% (DS)	3	86.3 (77.7-92.5)	90.2 (89.4-91.1)	9.21 (7.23-11.74)	0.17 (0.09-0.33)	52.33 (27.23-100.58)
CRC prevalence < 2.5% (Bv)	3	84.9 (73.4-92.0)	90.5 (89.0-91.9)	8.96 (7.63-10.53)	0.17 (0.09-0.30)	53.77 (26.99-107.11)

¹Values are expressed as percentages and its 95% confidence interval;

²Values are expressed as absolute numbers and its 95% confidence interval. Bv: Bivariate; CRC: Colorectal cancer; D: DerSimonian; LR: Likelihood ratio; OR: Odds ratio.